Press Releases
Date picker
Category
Results per page
Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology
Kancera AB (publ) today announces that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer and entered into…
Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
This is a translation of the interim report published in Swedish at October 26, 2022
Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies
Kancera AB (publ) reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. Preclinical studies of…
Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma
Regulatory
Kancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such…
Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients
Kancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted…
Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer
Kancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models…
Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
This is a translation of the interim report published in swedish on Januaryt 19th
Correction: Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851
Due to technical reasons this report was only published as a press release, but did not show up in the Finacial reports section on the Kancera web page. This is…
Kancera receives patent grant in US for the drug candidate KAND145
Kancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned…
Kancera provides operational update in connection with the interim report for the first quarter of 2022
This is a translation of a press release published in Swedish by Kancera AB (publ) on May 20, 2022.